Review



hu5c8  (ProSci Incorporated)


Bioz Verified Symbol ProSci Incorporated is a verified supplier
Bioz Manufacturer Symbol ProSci Incorporated manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    ProSci Incorporated hu5c8
    (A) CD40L binding potency of AT-1501 (cyan) and <t>Hu5C8</t> (orange) was determined by ELISA with recombinant human CD40L (rhuCD40L). Abatacept (purple), a variant of CTLA4-Ig that interferes with the CD28-CD80/86 costimulatory pathway, was used as a negative control. A450, absorbance at 450nm. (B) AT-1501 and Hu5C8 binding to human FcγRI, FcγRIIa, FcγRIIIa, and FcγRIIIb was measured by ELISA. (C to F) PAC-1 expression was measured in platelets from healthy controls incubated with soluble CD40L alone (C), Hu5C8 and sCD40L (D), Hu5C8 F(Ab’)2 lacking an Fc region and sCD40L (E), or AT-1501 and sCD40L (F). Blue tracings represent expression of PAC-1 following incubation with 5μg/mL sCD40L alone and red tracings represent expression of PAC-1 following incubation with the indicated combinations. (G) Platelet aggregation was measured in vitro using platelets incubated with the indicated combinations.
    Hu5c8, supplied by ProSci Incorporated, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/hu5c8/sCD40+Ligand+Antibody/pmc10990482-589-4-5
    Average 94 stars, based on 1 article reviews
    hu5c8 - by Bioz Stars, 2026-09
    94/100 stars

    Images

    1) Product Images from "The anti-CD40L monoclonal antibody AT-1501 promotes islet and kidney allograft survival and function in nonhuman primates"

    Article Title: The anti-CD40L monoclonal antibody AT-1501 promotes islet and kidney allograft survival and function in nonhuman primates

    Journal: Science translational medicine

    doi: 10.1126/scitranslmed.adf6376

    (A) CD40L binding potency of AT-1501 (cyan) and Hu5C8 (orange) was determined by ELISA with recombinant human CD40L (rhuCD40L). Abatacept (purple), a variant of CTLA4-Ig that interferes with the CD28-CD80/86 costimulatory pathway, was used as a negative control. A450, absorbance at 450nm. (B) AT-1501 and Hu5C8 binding to human FcγRI, FcγRIIa, FcγRIIIa, and FcγRIIIb was measured by ELISA. (C to F) PAC-1 expression was measured in platelets from healthy controls incubated with soluble CD40L alone (C), Hu5C8 and sCD40L (D), Hu5C8 F(Ab’)2 lacking an Fc region and sCD40L (E), or AT-1501 and sCD40L (F). Blue tracings represent expression of PAC-1 following incubation with 5μg/mL sCD40L alone and red tracings represent expression of PAC-1 following incubation with the indicated combinations. (G) Platelet aggregation was measured in vitro using platelets incubated with the indicated combinations.
    Figure Legend Snippet: (A) CD40L binding potency of AT-1501 (cyan) and Hu5C8 (orange) was determined by ELISA with recombinant human CD40L (rhuCD40L). Abatacept (purple), a variant of CTLA4-Ig that interferes with the CD28-CD80/86 costimulatory pathway, was used as a negative control. A450, absorbance at 450nm. (B) AT-1501 and Hu5C8 binding to human FcγRI, FcγRIIa, FcγRIIIa, and FcγRIIIb was measured by ELISA. (C to F) PAC-1 expression was measured in platelets from healthy controls incubated with soluble CD40L alone (C), Hu5C8 and sCD40L (D), Hu5C8 F(Ab’)2 lacking an Fc region and sCD40L (E), or AT-1501 and sCD40L (F). Blue tracings represent expression of PAC-1 following incubation with 5μg/mL sCD40L alone and red tracings represent expression of PAC-1 following incubation with the indicated combinations. (G) Platelet aggregation was measured in vitro using platelets incubated with the indicated combinations.

    Techniques Used: Binding Assay, Enzyme-linked Immunosorbent Assay, Recombinant, Variant Assay, Negative Control, Expressing, Incubation, In Vitro

    Related Articles

    Positive Control:

    Article Title: The anti-CD40L monoclonal antibody AT-1501 promotes islet and kidney allograft survival and function in nonhuman primates
    Article Snippet: Images of the stained gels were analysed on a BioSpectrum Imaging System (UVP). .. ELISAs were run with Hu5C8 (ProSci, XP-5263BT), an anti-CD40L antibody, as a positive control and Abatacept (Bristol Myers Squibb), a variant of CTLA4-Ig antibody that does not bind CD40L, as a negative control. ..

    Article Title: The anti-CD40L monoclonal antibody AT-1501 promotes islet and kidney allograft survival and function in nonhuman primates
    Article Snippet: Images of the stained gels were analysed on a BioSpectrum Imaging System (UVP). .. CD40L binding assays ELISAs were run with Hu5C8 (ProSci, XP-5263BT), an anti-CD40L antibody, as a positive control and Abatacept (Bristol Myers Squibb), a variant of CTLA4-Ig antibody that does not bind CD40L, as a negative control. ..

    Article Title: The anti-CD40L monoclonal antibody AT-1501 promotes islet and kidney allograft survival and function in nonhuman primates
    Article Snippet: .. ELISAs were run with Hu5C8 (ProSci, XP-5263BT), an anti-CD40L antibody, as a positive control. ..

    Article Title: The anti-CD40L monoclonal antibody AT-1501 promotes islet and kidney allograft survival and function in nonhuman primates
    Article Snippet: Signal was detected on a Spectramax fluorescent plate reader at 450 nm. .. FcγR binding assays ELISAs were run with Hu5C8 (ProSci, XP-5263BT), an anti-CD40L antibody, as a positive control. ..

    Variant Assay:

    Article Title: The anti-CD40L monoclonal antibody AT-1501 promotes islet and kidney allograft survival and function in nonhuman primates
    Article Snippet: Images of the stained gels were analysed on a BioSpectrum Imaging System (UVP). .. ELISAs were run with Hu5C8 (ProSci, XP-5263BT), an anti-CD40L antibody, as a positive control and Abatacept (Bristol Myers Squibb), a variant of CTLA4-Ig antibody that does not bind CD40L, as a negative control. ..

    Article Title: The anti-CD40L monoclonal antibody AT-1501 promotes islet and kidney allograft survival and function in nonhuman primates
    Article Snippet: Images of the stained gels were analysed on a BioSpectrum Imaging System (UVP). .. CD40L binding assays ELISAs were run with Hu5C8 (ProSci, XP-5263BT), an anti-CD40L antibody, as a positive control and Abatacept (Bristol Myers Squibb), a variant of CTLA4-Ig antibody that does not bind CD40L, as a negative control. ..

    Negative Control:

    Article Title: The anti-CD40L monoclonal antibody AT-1501 promotes islet and kidney allograft survival and function in nonhuman primates
    Article Snippet: Images of the stained gels were analysed on a BioSpectrum Imaging System (UVP). .. ELISAs were run with Hu5C8 (ProSci, XP-5263BT), an anti-CD40L antibody, as a positive control and Abatacept (Bristol Myers Squibb), a variant of CTLA4-Ig antibody that does not bind CD40L, as a negative control. ..

    Article Title: The anti-CD40L monoclonal antibody AT-1501 promotes islet and kidney allograft survival and function in nonhuman primates
    Article Snippet: Images of the stained gels were analysed on a BioSpectrum Imaging System (UVP). .. CD40L binding assays ELISAs were run with Hu5C8 (ProSci, XP-5263BT), an anti-CD40L antibody, as a positive control and Abatacept (Bristol Myers Squibb), a variant of CTLA4-Ig antibody that does not bind CD40L, as a negative control. ..

    Binding Assay:

    Article Title: The anti-CD40L monoclonal antibody AT-1501 promotes islet and kidney allograft survival and function in nonhuman primates
    Article Snippet: Images of the stained gels were analysed on a BioSpectrum Imaging System (UVP). .. CD40L binding assays ELISAs were run with Hu5C8 (ProSci, XP-5263BT), an anti-CD40L antibody, as a positive control and Abatacept (Bristol Myers Squibb), a variant of CTLA4-Ig antibody that does not bind CD40L, as a negative control. ..

    Article Title: The anti-CD40L monoclonal antibody AT-1501 promotes islet and kidney allograft survival and function in nonhuman primates
    Article Snippet: Signal was detected on a Spectramax fluorescent plate reader at 450 nm. .. FcγR binding assays ELISAs were run with Hu5C8 (ProSci, XP-5263BT), an anti-CD40L antibody, as a positive control. ..



    Similar Products

    hu5c8 fab region  (Tonix Pharmaceuticals)
    86
    Tonix Pharmaceuticals hu5c8 fab region
    Hu5c8 Fab Region, supplied by Tonix Pharmaceuticals, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/hu5c8/fab+hu5c8+region/pmc11568940-46-12-17
    Average 86 stars, based on 1 article reviews
    hu5c8 fab region - by Bioz Stars, 2026-09
    86/100 stars
    		  Buy from Supplier
    scd40l complexed to hu5c8, at-1501, or to hu5c8 f(ab’)2 lacking an fc region  (R&D Systems)
    90
    R&D Systems scd40l complexed to hu5c8, at-1501, or to hu5c8 f(ab’)2 lacking an fc region
    (A) CD40L binding potency of AT-1501 (cyan) and Hu5C8 (orange) was determined by ELISA with recombinant human CD40L (rhuCD40L). Abatacept (purple), a variant of CTLA4-Ig that interferes with the CD28-CD80/86 costimulatory pathway, was used as a negative control. A450, absorbance at 450nm. (B) AT-1501 and Hu5C8 binding to human FcγRI, FcγRIIa, FcγRIIIa, and FcγRIIIb was measured by ELISA. (C to F) PAC-1 expression was measured in platelets from healthy controls incubated with <t>soluble</t> <t>CD40L</t> alone (C), Hu5C8 and <t>sCD40L</t> (D), Hu5C8 F(Ab’)2 lacking an Fc region and sCD40L (E), or AT-1501 and sCD40L (F). Blue tracings represent expression of PAC-1 following incubation with 5μg/mL sCD40L alone and red tracings represent expression of PAC-1 following incubation with the indicated combinations. (G) Platelet aggregation was measured in vitro using platelets incubated with the indicated combinations.
    Scd40l Complexed To Hu5c8, At 1501, Or To Hu5c8 F(ab’)2 Lacking An Fc Region, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/hu5c8/scd40l/pmc10990482-472-13-10
    Average 90 stars, based on 1 article reviews
    scd40l complexed to hu5c8, at-1501, or to hu5c8 f(ab’)2 lacking an fc region - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    hu5c8  (ProSci Incorporated)
    94
    ProSci Incorporated hu5c8
    (A) CD40L binding potency of AT-1501 (cyan) and <t>Hu5C8</t> (orange) was determined by ELISA with recombinant human CD40L (rhuCD40L). Abatacept (purple), a variant of CTLA4-Ig that interferes with the CD28-CD80/86 costimulatory pathway, was used as a negative control. A450, absorbance at 450nm. (B) AT-1501 and Hu5C8 binding to human FcγRI, FcγRIIa, FcγRIIIa, and FcγRIIIb was measured by ELISA. (C to F) PAC-1 expression was measured in platelets from healthy controls incubated with soluble CD40L alone (C), Hu5C8 and sCD40L (D), Hu5C8 F(Ab’)2 lacking an Fc region and sCD40L (E), or AT-1501 and sCD40L (F). Blue tracings represent expression of PAC-1 following incubation with 5μg/mL sCD40L alone and red tracings represent expression of PAC-1 following incubation with the indicated combinations. (G) Platelet aggregation was measured in vitro using platelets incubated with the indicated combinations.
    Hu5c8, supplied by ProSci Incorporated, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/hu5c8/sCD40+Ligand+Antibody/pmc10990482-589-4-5
    Average 94 stars, based on 1 article reviews
    hu5c8 - by Bioz Stars, 2026-09
    94/100 stars
    		  Buy from Supplier
    anti-cd40l antibody hu5c8  (ProSci Incorporated)
    90
    ProSci Incorporated anti-cd40l antibody hu5c8
    (A) CD40L binding potency of AT-1501 (cyan) and <t>Hu5C8</t> (orange) was determined by ELISA with recombinant human CD40L (rhuCD40L). Abatacept (purple), a variant of CTLA4-Ig that interferes with the CD28-CD80/86 costimulatory pathway, was used as a negative control. A450, absorbance at 450nm. (B) AT-1501 and Hu5C8 binding to human FcγRI, FcγRIIa, FcγRIIIa, and FcγRIIIb was measured by ELISA. (C to F) PAC-1 expression was measured in platelets from healthy controls incubated with soluble CD40L alone (C), Hu5C8 and sCD40L (D), Hu5C8 F(Ab’)2 lacking an Fc region and sCD40L (E), or AT-1501 and sCD40L (F). Blue tracings represent expression of PAC-1 following incubation with 5μg/mL sCD40L alone and red tracings represent expression of PAC-1 following incubation with the indicated combinations. (G) Platelet aggregation was measured in vitro using platelets incubated with the indicated combinations.
    Anti Cd40l Antibody Hu5c8, supplied by ProSci Incorporated, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/hu5c8/hu5c8+xp+5263bt+antibody/pmc10990482-442-11-8
    Average 90 stars, based on 1 article reviews
    anti-cd40l antibody hu5c8 - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    hu5c8 scfv  (Cosmo Genetech Co)
    90
    Cosmo Genetech Co hu5c8 scfv
    (A) CD40L binding potency of AT-1501 (cyan) and <t>Hu5C8</t> (orange) was determined by ELISA with recombinant human CD40L (rhuCD40L). Abatacept (purple), a variant of CTLA4-Ig that interferes with the CD28-CD80/86 costimulatory pathway, was used as a negative control. A450, absorbance at 450nm. (B) AT-1501 and Hu5C8 binding to human FcγRI, FcγRIIa, FcγRIIIa, and FcγRIIIb was measured by ELISA. (C to F) PAC-1 expression was measured in platelets from healthy controls incubated with soluble CD40L alone (C), Hu5C8 and sCD40L (D), Hu5C8 F(Ab’)2 lacking an Fc region and sCD40L (E), or AT-1501 and sCD40L (F). Blue tracings represent expression of PAC-1 following incubation with 5μg/mL sCD40L alone and red tracings represent expression of PAC-1 following incubation with the indicated combinations. (G) Platelet aggregation was measured in vitro using platelets incubated with the indicated combinations.
    Hu5c8 Scfv, supplied by Cosmo Genetech Co, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/hu5c8/hu5c8+scfv/us11773176-568-16-30
    Average 90 stars, based on 1 article reviews
    hu5c8 scfv - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    humanized monoclonal antibody directed against human cd40l (hu5c8 or ruplizumab)  (Biogen Inc)
    90
    Biogen Inc humanized monoclonal antibody directed against human cd40l (hu5c8 or ruplizumab)
    (A) CD40L binding potency of AT-1501 (cyan) and <t>Hu5C8</t> (orange) was determined by ELISA with recombinant human CD40L (rhuCD40L). Abatacept (purple), a variant of CTLA4-Ig that interferes with the CD28-CD80/86 costimulatory pathway, was used as a negative control. A450, absorbance at 450nm. (B) AT-1501 and Hu5C8 binding to human FcγRI, FcγRIIa, FcγRIIIa, and FcγRIIIb was measured by ELISA. (C to F) PAC-1 expression was measured in platelets from healthy controls incubated with soluble CD40L alone (C), Hu5C8 and sCD40L (D), Hu5C8 F(Ab’)2 lacking an Fc region and sCD40L (E), or AT-1501 and sCD40L (F). Blue tracings represent expression of PAC-1 following incubation with 5μg/mL sCD40L alone and red tracings represent expression of PAC-1 following incubation with the indicated combinations. (G) Platelet aggregation was measured in vitro using platelets incubated with the indicated combinations.
    Humanized Monoclonal Antibody Directed Against Human Cd40l (Hu5c8 Or Ruplizumab), supplied by Biogen Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/hu5c8/cd40l+antibody/us11248055-31-7-12
    Average 90 stars, based on 1 article reviews
    humanized monoclonal antibody directed against human cd40l (hu5c8 or ruplizumab) - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    hu5c8 igg2σ antibody  (Janssen)
    90
    Janssen hu5c8 igg2σ antibody
    (A) CD40L binding potency of AT-1501 (cyan) and <t>Hu5C8</t> (orange) was determined by ELISA with recombinant human CD40L (rhuCD40L). Abatacept (purple), a variant of CTLA4-Ig that interferes with the CD28-CD80/86 costimulatory pathway, was used as a negative control. A450, absorbance at 450nm. (B) AT-1501 and Hu5C8 binding to human FcγRI, FcγRIIa, FcγRIIIa, and FcγRIIIb was measured by ELISA. (C to F) PAC-1 expression was measured in platelets from healthy controls incubated with soluble CD40L alone (C), Hu5C8 and sCD40L (D), Hu5C8 F(Ab’)2 lacking an Fc region and sCD40L (E), or AT-1501 and sCD40L (F). Blue tracings represent expression of PAC-1 following incubation with 5μg/mL sCD40L alone and red tracings represent expression of PAC-1 following incubation with the indicated combinations. (G) Platelet aggregation was measured in vitro using platelets incubated with the indicated combinations.
    Hu5c8 Igg2σ Antibody, supplied by Janssen, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/hu5c8/hu5c8+igg2%CF%83+antibody/us11150255-1259-10-15
    Average 90 stars, based on 1 article reviews
    hu5c8 igg2σ antibody - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    (A) CD40L binding potency of AT-1501 (cyan) and Hu5C8 (orange) was determined by ELISA with recombinant human CD40L (rhuCD40L). Abatacept (purple), a variant of CTLA4-Ig that interferes with the CD28-CD80/86 costimulatory pathway, was used as a negative control. A450, absorbance at 450nm. (B) AT-1501 and Hu5C8 binding to human FcγRI, FcγRIIa, FcγRIIIa, and FcγRIIIb was measured by ELISA. (C to F) PAC-1 expression was measured in platelets from healthy controls incubated with soluble CD40L alone (C), Hu5C8 and sCD40L (D), Hu5C8 F(Ab’)2 lacking an Fc region and sCD40L (E), or AT-1501 and sCD40L (F). Blue tracings represent expression of PAC-1 following incubation with 5μg/mL sCD40L alone and red tracings represent expression of PAC-1 following incubation with the indicated combinations. (G) Platelet aggregation was measured in vitro using platelets incubated with the indicated combinations.

    Journal: Science translational medicine

    Article Title: The anti-CD40L monoclonal antibody AT-1501 promotes islet and kidney allograft survival and function in nonhuman primates

    doi: 10.1126/scitranslmed.adf6376

    Figure Lengend Snippet: (A) CD40L binding potency of AT-1501 (cyan) and Hu5C8 (orange) was determined by ELISA with recombinant human CD40L (rhuCD40L). Abatacept (purple), a variant of CTLA4-Ig that interferes with the CD28-CD80/86 costimulatory pathway, was used as a negative control. A450, absorbance at 450nm. (B) AT-1501 and Hu5C8 binding to human FcγRI, FcγRIIa, FcγRIIIa, and FcγRIIIb was measured by ELISA. (C to F) PAC-1 expression was measured in platelets from healthy controls incubated with soluble CD40L alone (C), Hu5C8 and sCD40L (D), Hu5C8 F(Ab’)2 lacking an Fc region and sCD40L (E), or AT-1501 and sCD40L (F). Blue tracings represent expression of PAC-1 following incubation with 5μg/mL sCD40L alone and red tracings represent expression of PAC-1 following incubation with the indicated combinations. (G) Platelet aggregation was measured in vitro using platelets incubated with the indicated combinations.

    Article Snippet: FITC-PAC-1 (BD Biosciences, clone PAC-1) and tested reagents (sCD40L alone (R&D Systems, 6245-CL/CF); sCD40L complexed to Hu5C8, AT-1501, or to Hu5C8 F(Ab’)2 lacking an Fc region) were added and incubated for 30 minutes in the dark at room temperature before being diluted in PBS.

    Techniques: Binding Assay, Enzyme-linked Immunosorbent Assay, Recombinant, Variant Assay, Negative Control, Expressing, Incubation, In Vitro

    (A) CD40L binding potency of AT-1501 (cyan) and Hu5C8 (orange) was determined by ELISA with recombinant human CD40L (rhuCD40L). Abatacept (purple), a variant of CTLA4-Ig that interferes with the CD28-CD80/86 costimulatory pathway, was used as a negative control. A450, absorbance at 450nm. (B) AT-1501 and Hu5C8 binding to human FcγRI, FcγRIIa, FcγRIIIa, and FcγRIIIb was measured by ELISA. (C to F) PAC-1 expression was measured in platelets from healthy controls incubated with soluble CD40L alone (C), Hu5C8 and sCD40L (D), Hu5C8 F(Ab’)2 lacking an Fc region and sCD40L (E), or AT-1501 and sCD40L (F). Blue tracings represent expression of PAC-1 following incubation with 5μg/mL sCD40L alone and red tracings represent expression of PAC-1 following incubation with the indicated combinations. (G) Platelet aggregation was measured in vitro using platelets incubated with the indicated combinations.

    Journal: Science translational medicine

    Article Title: The anti-CD40L monoclonal antibody AT-1501 promotes islet and kidney allograft survival and function in nonhuman primates

    doi: 10.1126/scitranslmed.adf6376

    Figure Lengend Snippet: (A) CD40L binding potency of AT-1501 (cyan) and Hu5C8 (orange) was determined by ELISA with recombinant human CD40L (rhuCD40L). Abatacept (purple), a variant of CTLA4-Ig that interferes with the CD28-CD80/86 costimulatory pathway, was used as a negative control. A450, absorbance at 450nm. (B) AT-1501 and Hu5C8 binding to human FcγRI, FcγRIIa, FcγRIIIa, and FcγRIIIb was measured by ELISA. (C to F) PAC-1 expression was measured in platelets from healthy controls incubated with soluble CD40L alone (C), Hu5C8 and sCD40L (D), Hu5C8 F(Ab’)2 lacking an Fc region and sCD40L (E), or AT-1501 and sCD40L (F). Blue tracings represent expression of PAC-1 following incubation with 5μg/mL sCD40L alone and red tracings represent expression of PAC-1 following incubation with the indicated combinations. (G) Platelet aggregation was measured in vitro using platelets incubated with the indicated combinations.

    Article Snippet: ELISAs were run with Hu5C8 (ProSci, XP-5263BT), an anti-CD40L antibody, as a positive control.

    Techniques: Binding Assay, Enzyme-linked Immunosorbent Assay, Recombinant, Variant Assay, Negative Control, Expressing, Incubation, In Vitro